Emerging Therapies: The Role of GLP-1 Agonists and SGLT2 Inhibitors in PAD/CLTI Management. Impact on the Guidelines

<p>Within the prior 24 months, I have had a financial relationship with a company producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients: </p><ul><li>Grant Support/Research Contract - Bayer AG; AstraZenca; Medtronic; Merck/Schering Plough; Amgen; Janssen; Wraser; Cook Medical</li></ul>